Abstract
Various lockdown measures have been taken in different countries to mitigate the Covid-19 pandemic. But, for citizens, it is not always simple to understand how these measures have been taken. Should they have been more (or less) restrictive? Should the lockdown period have been longer (or shorter)? What would have been the benefits of starting to confine the population earlier? To provide some elements of response to these questions, we propose a simple behavior model for the government decision-making operation. Although simple and obviously improvable, the proposed model has the merit to implement in a pragmatic and insightful way the tradeoff between health and macroeconomic aspects. For a given tradeoff between the assumed cost functions for the economic and health impacts, it is then possible to determine the best lockdown starting date, the best lockdown duration, and the optimal severity levels during and after lockdown. The numerical analysis is based on a standard SEIR model and performed for the case of France but the adopted approach can be applied to any country. Our analysis, based on the proposed model, shows that for France it would have been possible to have just a quarter of the actual number of people infected (over [March 1, August 31]), while simultaneously having a Gross Domestic Product loss about 30% smaller than the one expected with the current policy
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
NA
